Bio tech company updates — 5/23/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech is making headlines on multiple fronts this week: Eli Lilly has deepened its partnership with Samsung Biologics while ramping up investment in Korea, and Joe Panetta, President Emeritus of BIOCOM, is urging Korea to act more aggressively in biotech investment as China gains ground. Meanwhile, global scholars gathered at KRIBB's advisory meeting highlighted biotechnology's expanding role beyond pharmaceuticals into food security, aging, and alternative fuels.
Key Findings
-
Eli Lilly deepens Korea ties with Samsung Biologics partnership: Marking its 150th anniversary, Eli Lilly has announced increased investment in Korea, spotlighting its partnership with Samsung Biologics and a new AI-driven drug discovery initiative at Songdo Gateway Labs.
-
U.S. biotech veteran urges Korea to act more aggressively: Joe Panetta, President Emeritus of BIOCOM, warned in an interview that while U.S. biotech investment is rebounding, Korea must move more aggressively to keep pace as China rapidly gains ground in global biotechnology.
-
KRIBB scholars: Biotech is key to solving food, aging, and fuel challenges: Global bio scholars convened at KRIBB's Overseas Scientific Advisory Committee emphasized that biotechnology is critical to addressing food crises, aging populations, and alternative fuel development — not just drug development.
Details
Eli Lilly Boosts Korea Investment, Partners Samsung Bio
Eli Lilly, celebrating its 150th anniversary, has significantly increased its commitment to the Korean biotech ecosystem. The company's Korean unit is touting AI-driven drug discovery capabilities and a new research facility, Songdo Gateway Labs, developed in partnership with Samsung Biologics. The collaboration underscores Korea's growing role as a biomanufacturing and pharmaceutical innovation hub, with global majors anchoring long-term relationships in the country.
Korea Urged to Move Faster as China Gains Biotech Ground
Joe Panetta, President Emeritus of BIOCOM — one of the largest life science industry associations in the United States — cautioned in a recent interview that the rebound of U.S. biotech investment is a positive signal for the sector globally, but that Korea in particular must adopt a more aggressive posture. With China accelerating its biotech capabilities and capital deployment, Korea risks falling behind if it does not match that pace with bolder investment strategies and ecosystem development.
KRIBB Advisory Committee: Biotech Beyond Pharma
Global biotechnology scholars attending KRIBB's (Korea Research Institute of Bioscience and Biotechnology) Overseas Scientific Advisory Committee meeting on May 21 argued that the scope of biotechnology must be viewed more broadly. According to attendees, biotech holds the key to solving pressing global challenges including food crises, the aging population, and the development of alternative fuels — extending the sector's relevance well beyond its traditional pharmaceutical focus.
Sources
- Eli Lilly marks 150 years, boosts Korea investment and partners Samsung Bio — Chosunbiz
- "U.S. biotech investment rebounds, but Korea told to act more aggressively as China gains ground" — THE BIO
- Biotech Holds Key to Solving Food, Aging Challenges, Global Scholars Say — Seoul Economic Daily
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
